GlobeNewswire by notified

€6.2 million in funding allocated by ADEME to Global Bioenergies’ Prénidem project

Share

€6.2 million in funding allocated by ADEME to Global Bioenergies’ Prénidem project

€4.4 million allocated to Global Bioenergies, €1 million allocated to Ajinomoto Foods Europe and €0.7 million allocated to ARD, the other two members of the consortium

Funding in the form of 60% subsidy (non-repayable) and 40% repayable advances, subject to the achievement of technical and commercial milestones, to be paid in several instalments over the duration of the project, including an initial 15% instalment.

Evry, 14 March 2023Global Bioenergies announces that it has received support from the French government as part of the “Biobased products and industrial biotechnologies” call for projects led by ADEME, in partnership with Ajinomoto Foods Europe, leader in industrial fermentation, and ARD, specialist in scale-up and exploitation of biotechnological processes. The project runs until September 2025.

The Prénidem project aims to implement the “two-step” production process on which Horizon 2 is based. The first step involves the conversion of residual sugars into DMA (also known as “prenic acid”). Production of this metabolic intermediate is carried out in an industrial-scale fermenter operated by Ajinomoto Foods Europe. The second step consists of converting this DMA into isobutene in the production unit owned by Global Bioenergies and operated by ARD at its Pomacle-Bazancourt facility.

The main goal of the project is to promote commercial applications of biobased isobutene derivatives in the make-up market as well as the high octane renewable fuel additives currently sought by Formula 1 stakeholders.

The second goal is to optimise the technology in order to reduce the production costs of biobased isobutene and its derivatives.

The project will boost the development of new green value industries in France by addressing the strategic challenges of economic sovereignty, income generation and employment.

Yves Duquesnoy, Deputy CEO of Ajinomoto Foods Europe, commented: “Our collaboration with Global Bioenergies started in 2021 and has gone from strength to strength since then: we have managed to scale up the DMA biological production process to 160,000 litres. We are very glad to be able to optimise industrial production thanks to government support.”

Philippe Aubry, Deputy CEO of ARD, said: “We have been working with Global Bioenergies since 2014 and as part of this project we bring our know-how to contribute to the industrialization of this radically innovative process. We produce the biocatalyst for the second step on an industrial size fermenter (180,000 litres), and carry out the second step itself (bioconversion of DMA into isobutene) on the Global Bioenergies reactor.”

Bernard Chaud, Head of Industrial Strategy at Global Bioenergies, said: “This government funding will allow us to optimise our Horizon 2 production chain and prepare the commercial roll-out of the ViaViridia plant, which corresponds to our Horizon 3, by offering significant volumes of biobased isobutene and derivatives to our customers and prospects.”

About GLOBAL BIOENERGIES

Global Bioenergies converts plant-derived resources into compounds used in the cosmetics industry, as well as the energy and materials sectors. After launching the first long-lasting and natural make-up brand LAST® in 2021, Global Bioenergies is now marketing Isonaturane® 12, its key ingredient, to major cosmetics companies to improve the naturalness of their formulas whilst improving their carbon footprint. In the long run, Global Bioenergies is also aiming at cutting CO2 emissions in the aviation and road sector and thereby curb global warming. Global Bioenergies is listed on Euronext Growth Paris (FR0011052257 - ALGBE).

Receive information about Global Bioenergies directly by subscribing to our news feed on www.global-bioenergies.com

Follow us on LinkedIn: Global Bioenergies

Contacts

GLOBAL BIOENERGIES



invest@global-bioenergies.com

PRESS RELATIONS



Iva Baytcheva
ibaytcheva@ulysse-communication.com



Nicolas Daniels
ndaniels@ulysse-communication.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

Robex Announces Share Consolidation29.3.2024 00:30:00 CET | Press release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES QUEBEC CITY, March 28, 2024 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX) announces today that its Board of Directors has approved the implementation of the consolidation of the issued and outstanding common shares of the Company approved by its shareholders on June 29, 2023, on the basis of one (1) post-consolidation common share for ten (10) pre-consolidation common shares (the "Consolidation"), which will take effect on April 1st, 2024 (the "Effective Date"). As a result, the Company's consolidated shares are expected to commence trading on the TSX Venture Exchange a few days after the Effective Date. After the Consolidation, the shares will have a new CUSIP number and a new ISIN number. The Consolidation will reduce the number of issued and outstanding common shares of the Company from approximately 844,054,403 common shares to 84,405,449 common shares upon complet

Golar LNG Limited - Announcement of filing of Form 20-F Annual Report28.3.2024 22:47:27 CET | Press release

Golar LNG Limited announces that it has filed its Form 20-F for the year ended December 31, 2023 with the Securities and Exchange Commission in the U.S. Form 20-F can be downloaded from the link below, is available on our website (www.golarlng.com) and shareholders may receive a hard copy free of charge upon request. March 28, 2024 The Board of Directors Hamilton, Bermuda Enquiries: Golar Management Limited: + 44 207 063 7900 Stuart Buchanan This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment GLNG 2023 Annual Report Form 20-F

HiddenA line styled icon from Orion Icon Library.Eye